Stockscreener 앱 받기
9.43
1.84%
0.17
시간 외 거래:
9.43
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com
Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com UK
Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times
Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan
GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance
Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India
Trend Tracker for (ARQT) - Stock Traders Daily
Arcutis biotherapeutics CMO sells $134,092 in stock - Investing.com India
Arcutis Biotherapeutics director sells $86,541 in stock - Investing.com
Arcutis biotherapeutics CMO sells $134,092 in stock By Investing.com - Investing.com UK
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
abrdn plc Buys 333,200 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8.7% HigherHere's Why - MarketBeat
AMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Jefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting - StockTitan
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis - Yahoo Finance
Health Canada approves Arcutis’ Zoryve foam for seborrheic dermatitis - World Pharmaceutical Frontiers
Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - BioSpace
SG Americas Securities LLC Reduces Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Behind the Bell: Arcutis Biotherapeutics - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2%Here's What Happened - MarketBeat
3.66%
1.11%
자본화:
|
볼륨(24시간):